Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05132504 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv12
  2. Primary and study completion dates: May 21, 2025 to May 21, 2027v11
  3. Primary completion date: Jul 30, 2024 to May 21, 2025 Completion date: Dec 31, 2024 to May 21, 2025v10 Show 1 more changeShow less
    • Completion date: Dec 31, 2024 to May 21, 2025
  4. Primary completion date: Jan 1, 2024 to Jul 30, 2024 Completion date: Jul 1, 2024 to Dec 31, 2024v9 Show 1 more changeShow less
    • Completion date: Jul 1, 2024 to Dec 31, 2024
  5. Study sites: 2 to 3 Eligibility criteria shortened, about 45 words · Collaborators: 1 to 2v8 Show 2 more changesShow less
    • Eligibility criteria shortened, about 45 words
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Eligibility criteria shortened, about 13 wordsv6 See this version in full on ClinicalTrials.gov ↗
  3. Eligibility criteria shortened, about 76 words Study description revisedv5 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 30, 2022 to Aug 31, 2022 · Site details revised at 2 of 2 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Sep 30, 2022 to Aug 31, 2022
    • Site details revised at 2 of 2 sites
  5. Start date: Apr 1, 2022 to Sep 30, 2022 Primary endpoint revised · Enrollment target: 27 to 30 · Secondary endpoints revised (4) · 1 morev3 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 27 to 30
    • Secondary endpoints revised (4)
    • Study description expanded, about 63 words

    See this version in full on ClinicalTrials.gov ↗

  6. Start date: Jan 1, 2022 to Apr 1, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months
Trial Details
NCT Number NCT05132504
Lead Sponsor Baylor College of Medicine
Collaborators: Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov